Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  SHANGHAI STOCK EXCHANGE  >  Tasly Pharmaceutical Group Co Ltd    600535   CNE000001C81

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Tasly Pharmaceutical Group Co Ltd : PPB Officials Visit Tasly (2013-09-29)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/30/2013 | 10:16pm CEST

A group of 5 officials led by Dr. Mwaniki, an official at the Registrar of the Pharmacy and Poisons Board (PPB) of Kenya and chairman of Pharmaceutical Society of Kenya, visited Tasly on Aug. 19 and held wide-ranging talks with senior officers, including Tasly International CEO Bill Dai.

PPB Officials with Tasly International Management

A PPB Official Complimenting Guotai Liquor

Visiting the International Communication Center, the production monitoring room of Tasly Pharmaceutical, the manufacturing facility of T89, the plant of Tasly Cooperative and some cultural landscapes inside the industrial park, the guests gave unanimous approval of and complimentary remarks on the scale of Tasly, the professional manufacturing facilities and the stringent quality control. Later in talks with CEO Dai, the officials listened to a detailed introduction of Tasly's corporate strength and international marketing and tried the Guotai Liquor. They expressed the hope that Tasly would market its premium products like modernized TCM, pharmaceutical chemical and API in Kenya to benefit the native people and recommend Guotai Liquor to high-end consumers in the country.

Lying in eastern Africa, Kenya is one of the wealthy countries in this part of continent. The nation with a population around 40m has a relatively mature drug market and is the largest pharmaceutical manufacturing and distribution market of COMESA (Common Market for Eastern and Southern Africa). Nevertheless, API is highly dependent on import due to insufficient production. Besides, the poor medical conditions prevalent in Eastern Africa also contribute to Kenya's considerable demand for pharmaceutical products and development potential.

Tasly has already formulated plans on vigorous development of indirect selling of pharmaceutical chemicals, APIs and modernized TCM drugs in Kenya. This tour by PPB officials focused on investigation of Tasly's scale of business and manufacturing capacity was organized to boost the mutual understanding and trust between Tasly and competent Kenyan agencies and pave the way for future entry into the pharmaceutical distribution market of the country.

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on TASLY PHARMACEUTICAL GROUP
07/20 TASLY PHARMACEUTICAL : Leaders from BRICS Ministry of Health Visited Tasly
06/07 TASLY PHARMACEUTICAL : Minister-counselor of Embassy of South America in Beijing..
05/10 TASLY PHARMACEUTICAL : Takes Stake in French Biomedicine Maker
04/17 TASLY PHARMACEUTICAL : Q1 Profit Up 15%
2016 TASLY PHARMACEUTICAL : won Top 20 of Most Competitive Pharmaceutical Listed Comp..
2016 TASLY PHARMACEUTICAL : listed in Top 100 of Chinese Pharmaceutical Industry in 2..
2016 TASLY PHARMACEUTICAL : Breakthrough in TCM Smart Manufacture Technology (2016-07..
2016 TASLY PHARMACEUTICAL : 2016 Shareholders’ Committee, Board of Directors, a..
2016 TASLY PHARMACEUTICAL : The Announcement of FDAⅢ Progress of Dantonic Pill ..
2015 TASLY PHARMACEUTICAL : The 26th China-US Joint Commission on Commerce and Trade ..
More news
Financials ( CNY)
Sales 2017 15 664 M
EBIT 2017 2 008 M
Net income 2017 1 442 M
Debt 2017 1 980 M
Yield 2017 1,32%
P/E ratio 2017 28,39
P/E ratio 2018 24,09
EV / Sales 2017 2,80x
EV / Sales 2018 2,52x
Capitalization 41 847 M
Chart TASLY PHARMACEUTICAL GROUP
Duration : Period :
Tasly Pharmaceutical Group Technical Analysis Chart | 600535 | CNE000001C81 | 4-Traders
Technical analysis trends TASLY PHARMACEUTICAL GROUP
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Average target price 43,6  CNY
Spread / Average Target 13%
EPS Revisions
Managers
NameTitle
Yong Hong Zhu General Manager & Director
Jian Zhong Zhang Chairman-Supervisory Board
Kai Jing Yan Chairman
Rui Hua Wang Chief Financial Officer
Xi Jun Yan Director
Sector and Competitors
1st jan.Capitalization (M$)
TASLY PHARMACEUTICAL GROUP CO LTD-6.65%6 274
JOHNSON & JOHNSON15.12%355 979
NOVARTIS7.69%216 915
ROCHE HOLDING LTD.3.78%216 699
PFIZER0.59%194 554
MERCK AND COMPANY4.45%167 705